Cover Image
市場調查報告書

PharmaPoint:週邊動脈阻塞性疾病 (PAD) - 全球醫藥品預測、市場分析 2024年

PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 349764
出版日期 內容資訊 英文 404 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:週邊動脈阻塞性疾病 (PAD) - 全球醫藥品預測、市場分析 2024年 PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
出版日期: 2015年10月01日 內容資訊: 英文 404 Pages
簡介

2014年的全球週邊動脈阻塞性疾病 (PAD) 市場規模,包含首發醫藥品、非專利處方藥雙方,達約5億4,340萬美金。全球PAD市場預計今後以約4.15%的年複合成長率大幅擴大,至2024年達到8億1,630美元的規模。

本報告提供全球週邊動脈阻塞性疾病 (PAD) 市場及醫藥品的相關調查,包含流行病學,病因,病理生理學,症狀,診斷,及治療指南的PAD概要,PAD治療藥市場年度收益,年度的治療成本及治療利用模式相關資料與預測,未滿足需求與機會分析,開發平台分析,全球PAD治療藥市場上現在與未來的競爭情形分析,及主要市場分析等彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 分類及癌症分期系統
  • 症狀及臨床表現
  • 預後
  • 生活品質

第4章 流行病學

  • 疾病的背景
  • 風險因素、共生病症
  • 全球趨勢
  • 預測手法
  • PAD的整體患病數的流行病學的預測
  • PAD的患病診斷數的流行病學的預測
  • 議論

第5章 疾病管理

  • 診斷、治療概要
  • 美國
  • 歐洲的主要5個市場
  • 日本
  • 中國都市區

第6章 競爭評估

  • 概要
  • 生活方式的變更
  • 風險因素修飾藥
  • 處理PAD的症狀的藥物療法
  • 藥物療法

第7章 未滿足需求、機會分析

  • 概要
  • 患者、醫生教育及PAD的認識的高漲,促進診斷、治療率
    • 未滿足需求
    • 差距分析
    • 機會
  • 以PAD患者為對象的實驗數多,可改善PAD管理的方針
  • 不僅治療間歇性跛行、危急性肢體缺血的症狀,也可防禦心血管系統活動的優秀藥物
  • 解明動脈粥狀硬化性心血管疾病的病因與病理學背後的複雜性質,帶來預防使其無效的治療可能性

第8章 開發平台評估

  • 概要
  • 後期階段臨床開發的有潛力醫藥品
  • 初期階段臨床開發的有潛力醫藥品

第9章 現在、未來的企業

  • 企業策略的概要、趨勢
  • 企業簡介

第10章 市場展望

  • 全球市場
  • 美國
  • 歐洲的主要5個市場
  • 日本
  • 中國都市區

第11章 附錄

圖表

目錄
Product Code: GDHC118PIDR

In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.'s Zontivity (vorapaxar), AstraZeneca's Brilinta (ticagrelor), and Bayer and Janssen's (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.

GlobalData believes that the size of the market for pharmacological agents designed to alleviate PAD symptoms, including cilostazol, naftidrofuryl, and pentoxifylline, will diminish throughout the forecast period. GlobalData accredits this diminishing to three factors: first, the advent of advanced revascularization procedures, as characterized by gradual, incremental improvements in success rates over time; second, the fact that current drug treatments, such as the ones mentioned above, display lackluster efficacy, perturbing safety attributes, and inconvenient dosing regimens; and third, the lack of novel, superior, premium-priced, drug therapies in the late stages of the PAD pipeline that could encroach on the patient shares of existing, rival pharmacological treatments.

The overall level of unmet need in the PAD market is high, resulting in a generous amount of room for new entrants to capitalize on. With respect to the first three traditional pillars of PAD treatment - antithrombotic pharmacological agents, lipid-lowering medical therapies, and antihypertensive drugs - the level of unmet need will fall once the current crop of late-phase PAD therapies portrayed in this report arrives onto the market. With respect to drugs that allay the symptoms of PAD, the level of unmet need here is astronomical. Present medical treatments are limited, archaic, and some have restricted availability.

Highlights

Key Questions Answered

  • From a clinical standpoint, there is a demand for novel medical therapies that target and relieve the symptoms of PAD in IC and CLI patients. KOLs interviewed by GlobalData expressed a desire for second-generation drug treatments that display superior efficacy and favorable safety profiles compared to existing pharmacological. Environmental unmet needs for this particular indication include physician education, patient awareness, greater screening, and improved guidelines. What other unmet needs exist in this market? Will the drugs under development fulfil the unmet needs of the PAD market?
  • The current late-stage PAD pipeline encompasses AstraZeneca's Brillinta, Bayer/Janssen's Xarelto and Merck's Zontivity. Will the late-stage drugs make a significant impact on the PAD market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

Key Findings

  • The major drivers of this expansion in the PAD market will be the advent of novel antithrombotic agents, such as Brilinta and Xarelto, onto the PAD stage, and the increasing prevalence of PAD across all of the 8MM.
  • The major global barrier to growth in the PAD market will be the losses of patent protection and market exclusivity on marketed and key pipeline drugs during the forecast period, such as AstraZeneca's Crestor (rosuvastatin), Sanofi's Plavix (clopidogrel), Brilinta, and Xarelto.
  • The overall level of unmet need in the PAD market is high, resulting in a generous amount of room for new entrants to capitalize on. GlobalData forecasts that once Brilinta and Xarelto, pipeline pharmacological agents currently in late-stage clinical trials for PAD, navigate their way through the regulatory landscape and secure approval for the PAD indication, they will address some of the unmet needs in this area.

Scope

  • Overview of peripheral artery disease (PAD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized PAD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PAD therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global PAD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global PAD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAD therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PAD therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification and Staging Systems
  • 3.3. Symptoms and Clinical Presentation
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024)
    • 4.5.1. Total Prevalent Cases of PAD
    • 4.5.2. Age-Specific Total Prevalent Cases of PAD
    • 4.5.3. Sex-Specific Total Prevalent Cases of PAD
    • 4.5.4. Age-Adjusted Total Prevalence of PAD
    • 4.5.5. Total Prevalent Asymptomatic and Symptomatic Cases of PAD
    • 4.5.6. Total Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia
    • 4.5.7. Proportion of Total PAD Cases that Present as Asymptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia
    • 4.5.8. Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes
  • 4.6. Epidemiological Forecast of Diagnosed Prevalent Cases of PAD (2014-2024)
    • 4.6.1. Diagnosed Prevalent Cases of PAD
    • 4.6.2. Age-Specific Diagnosed Prevalent Cases of PAD
    • 4.6.3. Sex-Specific Diagnosed Prevalent Cases of PAD
    • 4.6.4. Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD
    • 4.6.5. Diagnosed Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia
    • 4.6.6. Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia
    • 4.6.7. Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with Diabetes
  • 4.7. Discussion
    • 4.7.1. Epidemiological Forecast Insight
    • 4.7.2. Limitations of the Analysis
    • 4.7.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 5.2. US
  • 5.3. Five Major European Markets
  • 5.4. Japan
  • 5.5. Urban China

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Lifestyle Modifications
    • 6.2.1. Exercise
    • 6.2.2. Smoking cessation
  • 6.3. Risk Factor Modification Drugs
    • 6.3.1. Lipid-Lowering Medical Therapies
    • 6.3.2. Antihypertensive Medical Therapies
    • 6.3.3. Antithrombotic Medical Therapies
    • 6.3.4. Glucose-Lowering Medical Therapies
    • 6.3.5. Thrombolytic Therapies
  • 6.4. Medical Therapies Treating the Symptoms of PAD - Major Brands
    • 6.4.1. Pletal / Pletaal (cilostazol)
    • 6.4.2. Praxilene (naftidrofuryl oxalate)
    • 6.4.3. Trental (pentoxifylline)
    • 6.4.4. Prostaglandin and Prostanoid Medical Therapies
    • 6.4.5. Other Pharmacological Therapies
  • 6.5. Non-Pharmacological Therapies
    • 6.5.1. Revascularization

7. Unmet Need and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Enhanced Patient and Physician Education and Awareness of PAD, Facilitating Augmented Diagnosis and Treatment Rates
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. A Greater Number of Trials Exclusively Involving PAD Patients Will Yield Improved Guidelines for the Management of PAD
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Superior Pharmacological Agents that Treat the Symptoms of Intermittent Claudication and Critical Limb Ischemia, but also Obviate Cardiovascular Events
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Unravelling the Convoluted Nature Behind the Etiology and Pathophysiology of Atherosclerosis, Which Will Potentially Lead to Treatments that Prevent or Reverse Plaque Formation
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Late-Stage Clinical Development
    • 8.2.1. Xarelto (rivaroxaban)
    • 8.2.2. Brilinta (ticagrelor)
  • 8.3. Promising Drugs in Early-Stage Clinical Development
    • 8.3.1. Therapeutic Angiogenesis

9. Current and Future Players

  • 9.1. Overview and Trends in Corporate Strategy
  • 9.2. Company Profiles
    • 9.2.1. Bayer
    • 9.2.2. Janssen (Johnson & Johnson)
    • 9.2.3. AstraZeneca
    • 9.2.4. Merck & Co.
    • 9.2.5. Sanofi
    • 9.2.6. Pfizer
    • 9.2.7. Bristol-Myers Squibb
    • 9.2.8. Otsuka Holdings

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. Five Major European Markets
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Urban China
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed PAD Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Therapy Area Director
    • 11.6.3. Epidemiologist
    • 11.6.4. Global Head of Healthcare
    • 11.6.5. Global Director of Therapy Analysis and Epidemiology
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: The Various Causes of PAD
  • Table 2: The Rutherford-Baker System and the Fontaine Classification for PAD
  • Table 3: The Various Etiologies of ALI
  • Table 4: The Symptoms of PAD
  • Table 5: Risk Factors and Comorbidities for PAD
  • Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of PAD
  • Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Symptomatic and Asymptomatic Total Prevalent Cases of PAD
  • Table 8: 8MM, Sources of Epidemiological Data Used to Forecast the IC and CLI Total Prevalent Cases of PAD
  • Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of PAD with Hypertension or Diabetes
  • Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of PAD
  • Table 11: 8MM, Sources of Epidemiological Data Used to Forecast Asymptomatic and Symptomatic Diagnosed Prevalent Cases of PAD
  • Table 12: 8MM, Sources of Epidemiological Data Used for the Forecast of the Proportion of the Diagnosed PAD Population that Presents with IC
  • Table 13: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of PAD with Hypertension or Diabetes
  • Table 14: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Table 15: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N (Row %), 2014
  • Table 16: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014
  • Table 17: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 18: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N , 2014
  • Table 19: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 20: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Table 21: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014
  • Table 22: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014
  • Table 23: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 24: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N , 2014
  • Table 25: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 26: Population Characteristics of Individuals who Require Regular Screening for PAD
  • Table 27: Treatment Guidelines for PAD
  • Table 28: 8MM, Most Prescribed Drugs for PAD by Class, 2015
  • Table 29: Country Profile - US
  • Table 30: Country Profile - 5EU
  • Table 31: Country Profile - Japan
  • Table 32: Country Profile - Urban China
  • Table 33: Leading Drugs for PAD Treatment, 2015
  • Table 34: 8MM, Most Frequently Prescribed Lipid-lowering Medical Therapies
  • Table 35: Most Frequently Used Beta Blockers
  • Table 36: Product Profile - Beta Blockers
  • Table 37: Most Frequently Used ACE Inhibitors
  • Table 38: Product Profile - ACE Inhibitors
  • Table 39: Most Frequently Used ARBs
  • Table 40: Product Profile - ARBs
  • Table 41: Product Profile - Plavix (clopidogrel)
  • Table 42: Product Profile - Zontivity (vorapaxar)
  • Table 43: Efficacy and Bleeding Endpoints at Three Years in the TRA 2P-TIMI 50 Study
  • Table 44: Product Profile - Metformin
  • Table 45: Product Profile - Pletal (cilostazol)
  • Table 46: Safety Profile - Pletal (cilostazol)
  • Table 47: SWOT Analysis of Pletal, 2015
  • Table 48: Global Sales Forecast ($m) for Cilostazol, 2014-2024
  • Table 49: Product Profile - Praxilene (naftidrofuryl)
  • Table 50: Safety Profile - Praxilene (naftidrofuryl)
  • Table 51: SWOT Analysis of Praxilene, 2015
  • Table 52: Global Sales Forecast ($) for Naftidrofuryl, 2014-2024
  • Table 53: Product Profile - Trental (pentoxifylline)
  • Table 54: Most Frequently Recorded Side Effects for Pentoxifylline and Cilostazol.
  • Table 55: The Incidence (%) of Side Effects with Trental
  • Table 56: SWOT Analysis of Trental, 2015
  • Table 57: Global Sales Forecast ($m) for Pentoxifylline, 2014-2024
  • Table 58: Indications for Revascularization in PAD
  • Table 59: Major Unmet Needs and Opportunities in PAD
  • Table 60: Promising Drugs in Late-stage Clinical Development in the PAD Pipeline, 2015
  • Table 61: Comparison of Therapeutic Classes in Development for PAD, 2015
  • Table 62: Product Profile - Xarelto (rivaroxaban)
  • Table 63: SWOT Analysis of Xarelto, 2015
  • Table 64: 8MM, Sales Forecast ($m) for Xarelto, 2014-2024
  • Table 65: Product Profile - Brilinta (ticagrelor)
  • Table 66: Brilinta's Efficacy and Safety Endpoints as Three-Year Kaplan-Meier Estimates in the PEGASUS-TIMI 54 Study
  • Table 67: SWOT Analysis of Brilinta, 2015
  • Table 68: 8MM, Sales Forecast ($) for Brilinta, 2014-2024
  • Table 69: 8MM, Key Companies' Relevant Key Marketed and Pipeline Drugs in the PAD Market, 2015
  • Table 70: Bayer's PAD Portfolio Assessment, 2015
  • Table 71: Janssen's PAD Portfolio Assessment, 2015
  • Table 72: AstraZeneca's PAD Portfolio Assessment, 2015
  • Table 73: Merck's PAD Portfolio Assessment, 2015
  • Table 74: Sanofi's PAD Portfolio Assessment, 2015
  • Table 75: Pfizer's PAD Portfolio Assessment, 2015
  • Table 76: Bristol-Myers Squibb's PAD Portfolio Assessment, 2015
  • Table 77: Otsuka Pharmaceutical's PAD Portfolio Assessment, 2015
  • Table 78: 8MM Sales Forecast ($m) for PAD, 2014-2024
  • Table 79: 8MM, PAD Market - Drivers and Barriers, 2015
  • Table 80: 8MM, Sales Forecast ($m) for PAD in the US, 2014-2024
  • Table 81: Key Events Impacting Sales for PAD in the US, 2014-2024.
  • Table 82: US PAD Market - Drivers and Barriers, 2014-2024.
  • Table 83: Sales Forecast ($m) for PAD in the 5EU, 2014-2024
  • Table 84: Key Events Impacting Sales for PAD in the 5EU, 2014-2024
  • Table 85: 5EU PAD Market - Drivers and Barriers, 2014-2024
  • Table 86: Sales Forecast ($m) for PAD in Japan, 2014-2024
  • Table 87: Key Events Impacting Sales for PAD in Japan, 2014-2024
  • Table 88: PAD Market - Japan Drivers and Barriers, 2014-2024
  • Table 89: Sales Forecasts ($m) for PAD in Urban China, 2014-2024
  • Table 90: Key Events Impacting Sales for PAD in China, 2014-2024
  • Table 91: China PAD Market -Drivers and Barriers, 2014-2024
  • Table 92: Abbreviations
  • Table 93: Key Launch Dates
  • Table 94: Key Patent Expiries
  • Table 95: High-Prescribing Physicians Non-KOLs Surveyed, By Country

List of Figures

  • Figure 1: Clinical Manifestations of PAD
  • Figure 2: Progression of PAD, Atherosclerotic Plaque Rupture and Thrombosis.
  • Figure 3: 8MM, Patient Flow for the Epidemiological Forecast of PAD
  • Figure 4: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Figure 5: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N, 2014
  • Figure 6: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N, 2014
  • Figure 7: 8MM, Age-Standardized Total Prevalence of PAD, 2014
  • Figure 8: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 9: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 10: 8MM, Proportion of Total PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %
  • Figure 11: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 12: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Figure 13: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014
  • Figure 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N, 2014
  • Figure 15: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 16: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 17: 8MM, Proportion of Diagnosed PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %, 2014
  • Figure 18: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 19: The Most Common Tests Used to Diagnose PAD in US Patients, 2014
  • Figure 20: Breakdown of US PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014
  • Figure 21: The Most Common Tests Used to Diagnose PAD in 5EU Patients, 2014
  • Figure 22: Breakdown of 5EU PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014
  • Figure 23: The Most Common Tests Used to Diagnose PAD Patients in Japan, 2014
  • Figure 24: Percentage (%) Breakdown of Japan PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014
  • Figure 25: The Most Common Tests Used to Diagnose PAD Patients in China, 2014
  • Figure 26: Breakdown of Chinese PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014
  • Figure 27: 8MM, Percentage (%) of PAD Patients Referred to Specialist Secondary or Tertiary Care by Primary Care Physicians, 2014
  • Figure 28: The Various Marketed and Pipeline Antithrombotic Medical Therapies for PAD
  • Figure 29: The Treatment Algorithm for IC Patients
  • Figure 30: The Treatment Algorithm for CLI Patients
  • Figure 31: The Treatment Algorithm for ALI Patients
  • Figure 32: Competitive Assessment of Late-Stage Pipeline Agents in PAD, 2014-2024
  • Figure 33: Company Portfolio Gap Analysis in PAD, 2014-2024
  • Figure 34: Global Sales for PAD by Region, 2014 and 2024
  • Figure 35: 8MM, Global PAD Sales by Drug Class, 2014 and 2024
  • Figure 36: Sales for PAD in the US by Drug Class, 2014 and 2024
  • Figure 37: Sales for PAD in the 5EU by Drug Class, 2014 and 2024
  • Figure 38: Sales for PAD in Japan by Drug Class, 2014 and 2024
  • Figure 39: Sales for PAD in China by Drug Class, 2014 and 2024
Back to Top